Hosted on MSN

FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
Hosted on MSN

Edwards solidifies TAVR dominance in long-term trial readout

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Medscape

SURTAVI: TAVR, Surgical Aortic-Valve Replacement Stand Toe-to-Toe in Intermediate-Risk Patients

WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...
FierceBiotech

At ESC 2025, new heart valve guidelines call for earlier TAVR as implant makers expand reach

At the annual meeting of the European Society of Cardiology (ESC), being held this weekend in Madrid, new cardiac care guidelines call for a more uniform, simplified and accessible approach to ...